Tenax Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Tenax Therapeutics

14/05/2024 15:25

* Tenax Therapeutics Inc  TENX.OQ  reported a quarterly
adjusted
loss of $3.12​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of $-12.00.  The mean expectation of two analysts for the
quarter was for a loss of $2.40 per share. Wall Street expected
results to range from $-3.06 to $-1.74 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Tenax Therapeutics Inc's reported EPS for the quarter was
a loss
of $3.12​.
    * The company reported a quarterly loss of $3.8 million.
    * Tenax Therapeutics Inc shares had fallen by 16.3% this
quarter and lost 83.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 46.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Tenax
Therapeutics Inc is $32.50 
This summary was machine generated from LSEG data May 14 at
02:25 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -2.40          -3.12          Missed
 Dec. 31 2023      -8.14          -12.98         Missed
 Sep. 30 2023      -7.20          -6.40          Beat
 Jun. 30 2023      -8.00          -4.00          Beat